Education

All about writing- RxPharmacist Internship Testimonial

All about writing- RxPharmacist Internship Testimonial

Throughout my experience in the world of health care, I’ve learned that one of the most important skills a clinician can have is writing. I have discovered that the pharmacists and physicians who can expertly navigate a patient case and process large amounts of data are the same ones who have published numerous papers and have excellent writing/technical skills. Throughout pharmacy school, I have sought to fine-tune my writing skills by joining and later becoming Editor-in-Chief of EMSOP Chronicles, a student run newspaper service for the Ernest Mario School of Pharmacy. Additionally, I participated in a rigorous research project to test the effects of sulfur mustard on the corneas where I learned valuable skills in writing a scientific thesis.

After graduating pharmacy school, I sought to refine my writing skills further by taking on new challenges and accepting an intern position with RxPharmacist. My job was to create a study guide and practice questions for the New Jersey Multistate Pharmacy Jurisprudence Examination (MPJE). This opportunity was especially educational as I was able to transition my writing skills from scientific/technical writing to study guides that can be easily read and understood. The amazing and supportive team at RxPharmacist gave me the necessary resources to guide me in creating the best version of my study guide. With their help, I had the opportunity to assist students across New Jersey with not only passing but excelling at their pharmacy licensing exam.

I am very thankful for RxPharmacist for giving me the opportunity to learn, make mistakes, and cultivate my writing skills which ultimately makes me a better clinician. My goal is to progress further and build on my skills by continuing my education at the Robert Wood Johnson Medical School. I believe that by entering medical school, I will find more opportunities to write and gain new perspectives to write about.

-Musab S., 2021 RxPharmacist Graduate Intern

Rutgers University, Ernest Mario School of Pharmacy, Class of 2021

All about writing- RxPharmacist Internship Testimonial Read More »

Taking a risk, leading to a phenomenal reward

Taking a risk, leading to a phenomenal reward

The RxPharmacist internship program is an absolute must for anyone that feels even the slightest pull towards pursuing a pharmacy career that is non-traditional. Not only do you get paid to study, you get daily interactions with an army of mentors ready to help you with networking, job hunting, CV writing, and LinkedIn polishing.

The RxPharmacist team hosted many personalized workshops to help the interns transition from student to pharmacist, and more importantly, succeeding in their first job right out of school.

From step one my journey with RxPharmacist has been in my control, I was allowed to make my own project schedule and also make my MPJE guide exactly how I wanted. I was EXTREMELY nervous to sign on, I was concerned it would be too much to do with work, having a family, job hunting, and studying for the NAPLEX and MPJE, but I am so glad I bet on myself and the support RxPharmacist provided to take on this internship program. I have a completely unique addition to my CV, a new mentoring network, and an incalculable boost to my confidence. 

I would highly recommend anyone who is eyeing this internship to apply! It is a highly competitive process, but well worth it.

-Ally B., 2021 RxPharmacist Graduate Intern

University of Minnesota College of Pharmacy, Class of 2021

Taking a risk, leading to a phenomenal reward Read More »

The Compounding Conundrum of Personalized Medicine

It is no wonder personalized medicine has been taking a rise, after all the one size fits all approach seen in manufactured medicine cannot work for everyone. For patients with unique healthcare needs, compounding can be incredibly useful but the catch is these medications do not actually go through a traditional approval process. Why is that important? It means these medications and products have not been reviewed, studied, and evaluated by a third party regulatory entity such as the Food and Drug Administration (FDA).

Compounding is defined as the process of “combining, mixing, or altering ingredients to create medications tailored to the needs of an individual patient”.1 For example, a patient with allergies to certain ingredients in a medication such as a preservative or dye can receive a modified compounded form instead.1 Another example is a patient who may require an alternate dosage form such as a liquid as opposed to a tablet which is especially prominent in pediatric or geriatric populations.1

Access to compounding services are invaluable for some patients, however, vigilance is critically important in this particular field of practice. In the absence of FDA review and approval, guaranteeing the safety, efficacy and quality of these medications can be tricky… so tricky you might even call it a compounding conundrum. The interactable module below outlines common pharmaceutical ingredients used in compounding.3

In 2012, a Massachusetts pharmacy caused more than 750 infections and more than 60 fatalities across 20 states due to fungal contamination.2 This event would lead to passing of the Drug Quality and Security Act (DQSA) which was officially enacted the following year.2 A prior blog post of ours outlined the need for REMS programs and Why We Can’t Be Hasty When It Comes to Drug Safety, the same is particularly true here as patients can be placed in serious harms way when appropriate measures or precautions are not taken in compounding. The following links below assembled by the United States Pharmacopeial (USP) Convention are highly useful in better understanding appropriate standards for compounding and have been linked below for your convenience: 

The FDA also provides a plethora of compounding guidance and resources found here as it is trying to gain a more involved approach given the recent deaths and news from a lack of quality assurance or sterility in compounded products causing patient harm. For example, there is a federal law that specifies a 5% limit on distribution for out of state drugs compounded by pharmacies and physicians under Section 503A of the FDCA. The FDA plans not to enforce this rule until after states sign and finalize the memorandum of understanding (MOU) as ultimately it is under the state jurisdiction and regulation to oversee compounding pharmacies. 

References

  1. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Accessed May 6, 2021. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers.
  2. U.S. Food and Drug Administration. Compounding Laws and Policies. Accessed May 6, 2021. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers.
  3. Ansel, HC, Loyd VA. Pharmaceutical Dosage Forms And Drug Delivery Systems. 10th ed. Lippincott-Williams & Wilkins; 2014.

The Compounding Conundrum of Personalized Medicine Read More »

Rising Rates of Asthma and the Hygiene Hypothesis

Many years ago, I came across a tale of The Wheezing Wolf and the Three Little Pigs , you could call it a breathless spin on a timeless children’s classic. It is also a tale that manages to very creatively highlight a disease state which affects a large number of children worldwide, specifically asthma. It is estimated more than 22 million people (~6 million children) in the United States have some form of asthma, a chronic but reversible condition which causes inflammation and bronchoconstriction of our airways.1

Although there is no magic bullet or cure for people who suffer from asthma, we do have a large variety of medications that allow for proper management to help prevent long term airway remodeling, permanent lung damage, hospital stays and emergency room visits.1 You might be wondering what causes people to acquire asthma. Data is gathered meticulously to better highlight trends in asthma for this very reason. For example, one trend already identified makes clear that African American and Hispanic children are generally more likely to experience mortality from asthma related causes.1 Below you will find several interactable modules which outline the rise in asthma cases over time and the demographic aggregation of cases across the United States.

One theory which has gained traction over the years to explain rising cases of asthma is called the hygiene hypothesis. This hypothesis suggests our post natal immune response is compromised by an ultra clean environment.3 There is evidence to suggest lower levels of the bacterial protein lipopolysaccharide (LPS) in a person’s home would predispose them to develop conditions like asthma (LPS helps our immune system grow and learn by switching on toll-like receptor 4 (TLR4) on T-cells).3 If you would like to learn more about how this may relate to the COVID-19 pandemic, the following article is a nice read: The hygiene hypothesis, the COVID pandemic, and consequences for the human microbiome.

As a whole, asthma attacks can vary in severity and in nature from one person to another. Common triggers include tobacco smoke, dust mites, pollen, air pollution, mold, a man’s best friend, perfumes, harsh cleaners/disinfectants and even acid reflux.2 It is important for patients who suffer from asthma to identify and avoid triggers. For example, encouraging tobacco cessation in households with smokers or using an air cleaner with a HEPA filter for people who may be allergic to their furry friends.2

Lastly, if there is one thing we know from the hygiene hypothesis, it’s that people love to clean their homes. It is especially true now perhaps more than ever before and we may very well see an even steeper rate of asthma cases moving forward, even if just from COVID sequelae alone. Here is a CDC guide for properly cleaning and disinfecting homes that patients (especially those sensitive to harsh detergents or cleaners) may find useful; it’s even COVID approved. 

References

  1. U.S. Food and Drug Administration. Asthma Fact Sheet. Accessed May 2, 2021. Retrieved from https://www.fda.gov/consumers/minority-health-and-health-equity/asthma-fact-sheet.
  2. Centers for Disease Control and Prevention. Common Asthma Triggers. Accessed May 2, 2021. Retrieved from https://www.cdc.gov/asthma/triggers.html.
  3. U.S. Food and Drug Administration. Asthma: The Hygiene Hypothesis. Accessed May 2, 2021. Retrieved from https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/asthma-hygiene-hypothesis.
  4. National Center for Health Statistics, Centers for Disease Control and Prevention. Asthma Data Visualizations. Accessed May 2, 2021. https://www.cdc.gov/asthma/data-visualizations/default.htm.

Rising Rates of Asthma and the Hygiene Hypothesis Read More »

board, school, dreams

Mentorship and Networking – Beyond a Job!

Before my graduation in 2020, I was uncertain about my career and future with pharmacy being heavily saturated and the COVID-19 pandemic hit creating an ecomonic downturn. I first came across the summer internship at RxPharmacist because I recognized the opportunities that they offered including the flexibility of a remote work role, creating my own study guide, and achieving growth in medical technical writing and growing my professional network. Now as I complete the program, I am glad to share with you this incredible experience at RxPharmacist. 

My first project was to edit the CPJE guide, which aided me passing the exam on my first attempt. Besides providing feedback on my work performance, my inspiring mentor spent time discussing with me about entrepreneurship, marketing, and my career goal. There was a heavy emphasis on strategy to approach achieving my goals of attaining my dream fellowship program. For example, knowing my interest in the pharmaceutical industry, she introduced me to experts in the field and helped me on my CV, letter of intent, and practicing with mock interviews. Thanks to her unwavering support, I got accepted into my top choice fellowship program where I would practice as a clinical development fellow in oncology at Rutgers (2021-2023). Although I was already working as a full-time pharmacist, this remote job was so flexible that it allowed me to work on my own schedule. Needless to say, beyond a job, not only the internship offered a unique opportunity to expand my networks and writing skills, but it also was a good transition for me from a graduate student to a pharmacist. I’m incredibly thankful of being able to get into my top fellowship program with the unwavering support of RxPharmacist and also was able to gain the FDA ORISE fellowship as a backup opportunity should I not be able to get my top choice through their help.

Therefore, I highly recommend this internship to anyone who seeks for professional networks and experience in medical and scientific communications. The preceptors and team are highly supportive. If your willing to work hard, learn new skills, and try something new, this might be a wonderful opportunity for you.

Thi N., 2020-2021 RxPharmacist Graduate Intern

UC San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences, Class of 2020

Mentorship and Networking – Beyond a Job! Read More »

The Fault in Our EGFRs

The Fault in Our Stars is a novel written by John Green. Since its release in both print and film, the moving story has managed to strangle hearts around the world as it explores many colorful yet melancholic themes of life, cancer being among them. One example is a clever nod to Shakespeare’s Julius Caesar, specifically the following line by Caddius: “The fault, dear Brutus, is not in our stars, but in ourselves, that we are underlings”. 6

Of all the literary works I’ve read and enjoyed over the years, this line is especially memorable. Caddius implies fate (or stars for that matter) is a negligible force, for it is supposedly a person’s own fault alone if their life falls short of their expectations. By titling his book The Fault in Our Stars it is clear Green disagrees, at least as it pertains to cancer and our dear protagonists in the novel.

Although cancer can certainly be acquired through environmental means such as smoking or radiation, it can also be genetic. In fact, if we want to get a little more technical, for a select group of people their undoing could specifically be a fault in their epidermal growth factor receptor or EGFR (HER1/ErbB1) gene.2 EGFR positive lung cancer is most common in people who have adenocarcinoma, never/rarely smoked, women, young adults and people of asian or east asian heritage.2 Additionally, adenocarcinoma is a subtype of non-small cell lung cancer (NSCLC) which causes nearly 80-85% of all lung cancers.4 Risk of acquiring adenocarcinoma is increased for patients who smoke, inhale second hand smoke, and are exposed to radon gas, asbestos or other cancer-causing agents in their daily lives.4

If we are dealing with an EGFR positive case of lung cancer and wish to decide on a medication, it makes sense we would attempt targeted therapy as opposed to standard chemotherapy in order to directly inhibit the EGFR receptor. Therefore, NSCLC EGFR+ patients can typically be administered EGFR inhibitors as outlined above.

I have included some other potential mutations and their therapies as a bonus. Note they all end in -nib, as they are all tyrosine kinase inhibitors (TKIs) and the bolded drugs are preferred. Medications ending in ‘-mab’ denote monoclonal antibodies which are biologic type medications as they are usually therapeutic proteins and large structures chemically. Medications ending in ‘-nib’ are usually small molecules, think of this as a car versus an airplane which are ‘-mabs’ for size.

You should anticipate a rise in biosimilar oncology medications on the market. Overall, the Food and Drug Administration (FDA) has approved 29 biosimilar medications so far, and almost all of them have a role to play in oncology therapeutics. If you are interested in a much deeper dive into oncology and many more disease state topics, check out our CPJE Study Guide. Additionally, here are some useful resources on cancer you can also reference:

References

  1. American Cancer Society. What Causes Cancer? Accessed April 17, 2021. https://www.cancer.org/cancer/cancer-causes.html.
  2. Lung Cancer Foundation of America. EGFR Mutation and Lung Cancer: What is it and how is it treated? Accessed April 17, 2021. https://lcfamerica.org/lung-cancer-info/types-lung-cancer/egfr-mutation/.
  3. American Cancer Society. What Is Lung Cancer? Accessed April 17, 2021. https://www.cancer.org/cancer/lung-cancer/about/what-is.html.
  4. Harvard Health Publishing. Adenocarcinoma of the lung. Accessed April 17, 2021. https://www.health.harvard.edu/a_to_z/adenocarcinoma-of-the-lung-a-to-z.
  5. American Cancer Society. Non-Small Cell Lung Cancer Targeted Drug Therapy: Lung Cancer Drugs. Accessed April 17, 2021. https://www.cancer.org/cancer/lung-cancer/treating-non-small-cell/targeted-therapies.html.
  6. Shakespeare W, Mowat, BA, Werstine, P. The tragedy of Julius Caesar. New York: Washington Square Press; 2005.
  7. Green, J. The Fault in Our Stars. Penguin Books; 2013.

The Fault in Our EGFRs Read More »

Five Varieties of Insulin and Why We Need Them

An estimated 34.2 million people in the United States have some form of diabetes (⅕ of which are entirely unaware), and in the last 20 years the number of diagnosed adults has more than doubled in size.1 The significance of this disease state is paramount from a public health perspective, especially as diabetes has been identified as the number one cause of kidney failure, lower limb amputations and microvascular complications.1 You can think of diabetes as a metabolic disease which is generally broken down into four categories: type one diabetes, type two diabetes, gestational diabetes (onset during pregnancy) and prediabetes (elevated blood glucose levels which are yet to be considered entirely diagnostic of active disease).1

The following video is an excellent visual resource for understanding diabetes and its associated consequences on the human body.6 Both type one and type two diabetes cause an accumulation of glucose in the bloodstream, however, it is the etiology that differentiates them. Type one diabetics essentially experience autoimmune destruction of their pancreatic beta cells which diminishes endogenous insulin production (type one is usually diagnosed in younger people and makes up 5-10% of diabetics).1 In comparison, type two diabetics can produce insulin just fine but their body is unresponsive due to built up insulin resistance over time (type two is usually diagnosed in adults and makes up 90-95% of diabetics).1

The tricky thing about insulin is it must be injected because it is easily broken down and digested in an oral form.2 All patients with type one diabetes will be dependent on exogenous insulin for survival, and some type two diabetics may also require insulin for adequate control. There is a highly interesting concern in type two diabetes management surrounding a delay in insulin initiation, typically dubbed clinical inertia. You can read more about clinical inertia in the following literature review: Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review.

Insulins can be deadly when used inappropriately. It is important to understand and be familiar with the onset, peak and duration of insulins as seen in the figures above so an appropriate personalized regimen or adjustment can be made for each patient’s needs and goals. Generally, rapid and short acting insulins are intended for bolus purposes, whereas intermediate and long acting insulins are intended for basal purposes. We can also categorize and identify insulins via the five categories above. Note that Afrezza is inhaled as opposed to injected and can be given at the start of each meal which may be a great option if a patient is looking for something non-injectable.

As an aside, one important public health issue as it relates to insulins is actually affordability. Supposedly one in four diabetic patients cannot afford their insulin altogether.4 The issue is complex and significant enough to have its own dedicated gofundme page as for many patients insulins are a non-negotiable lifeline. You can read more about the black market dedicated to the insulin trade here, but remember there are resources for patients who need them should you ever directly encounter this issue in the community. Some patients may also obtain over the counter insulin from Walmart’s ReliOn insulin program.

References

  1. Centers for Disease Control and Prevention. What is Diabetes? Accessed April 6, 2021. https://www.cdc.gov/diabetes/basics/diabetes.html.
  2. American Diabetes Association. Insulin Basics. Accessed April 6, 2021. https://www.diabetes.org/healthy-living/medication-treatments/insulin-other-injectables/insulin-basics.
  3. Insulin and diabetes. Accessed April 6, 2021. https://www.diabetes.org.uk/guide-to-diabetes/managing-your-diabetes/treating-your-diabetes/insulin.
  4. About Mealtime Insulin. Accessed April 6, 2021. https://www.humalog.com/fast-acting-mealtime-insulin.
  5. Teare, K. One in four patients say they’ve skimped on insulin because of high cost. Accessed April 6, 2021. https://news.yale.edu/2018/12/03/one-four-patients-say-theyve-skimped-insulin-because-high-cost.
  6. Diabetes UK. Diabetes and the body | Diabetes UK. Published September 3, 2013. Accessed April 6, 2021. https://www.youtube.com/watch?v=X9ivR4y03DE.

Five Varieties of Insulin and Why We Need Them Read More »

Why We Can’t Be Hasty When It Comes to Drug Safety

To be, or not to be?

When it comes to drug safety, it is up to the U.S. Food and Drug Administration (FDA) to decide if a medication may be, or not be. The Risk Evaluation and Mitigation Strategy (REMS) requirement was set up by the FDA for select prescription medications which pose a high potential for serious adverse effects. As its name suggests, the REMS program is concerned with drug safety and in ensuring the benefits of a certain drug outweigh the risk.1

REMS does not only oversee adverse effects alone, but seeks to “prevent, monitor and manage” any medication the FDA expects could potentially violate safe medication practices.1 Although the FDA is in charge of determining whether REMS must be enforced for a medication, it is the manufacturer who is in charge of the program and submission of assessment reports for quality improvement or assurance efforts.2 Appendix 4 from A Framework for Benefit-Risk Counseling to Patients About Drugs with a REMS is a tool provided by the FDA which can be useful if you ever find yourself counselling a patient on a REMS classified drug.4

Drug safety efforts and their importance in public health can be seen as early as 1937. The antibiotic sulfonamide would result in hundreds of deaths due to the toxic excipient diethylene glycol supposedly claimed as being inert, you can read more about the incident via the June 1981 issue of the FDA Consumer magazine titled “sulfonamide disaster”.3 Later in the 1960s thalidomide was used for antiemetic effects in pregnant women, but resulted in severe teratogenic adverse effects made clear when babies were born with missing or deformed extremities.3

Science Museum Group. Thalomid (thalidomide) capsules. 2000-590 Science Museum Group Collection Online. Accessed March 13, 2021. https://collection.sciencemuseumgroup.org.uk/objects/co498098/thalomid-thalidomide-capsules-thalidomide.

Science Museum Group. Pair of artificial arms for a child, Roehampton, England, 1964. 1999-579 Science Museum Group Collection Online. Accessed March 13, 2021. https://collection.sciencemuseumgroup.org.uk/objects/co476754/pair-of-artificial-arms-for-a-child-roehampton-england-1964-artificial-arm.

The difference between these two events, however, is significant from the perspective of the United States. You see, after the sulfonamide tragedy the FDA mandated the 1938 Food, Drug, and Cosmetic Act (FDCA). At this point, pharmaceutical companies were required to conduct studies proving a drug is safe before becoming readily available to the general public.3 As such, thalidomide was never approved in the United States due to data suggesting deformities in animal models despite lobbying and immense political pressure against the clinical director at the time.3 

This brief dive into history barely scratches the surface on the importance of pharmacovigilance but is helpful in understanding what can happen if we get a little too hasty when it comes to drug safety, which brings us back to REMS. You can view a list of all current REMS medications on the FDA website alongside their associated goals, materials and a comprehensive timeline of program updates. Additionally, if you want to go really deep into the U.S. regulations for REMS, visit this helpful FDA slidedeck.

References

  1. Center for Drug Evaluation, Research. Risk Evaluation and Mitigation Strategies (REMS). Accessed March 13, 2021. https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems.
  2. Center for Drug Evaluation, Research. FAQs about REMS. Accessed March 13, 2021. https://www.fda.gov/drugs/risk-evaluation-and-mitigation-strategies-rems/frequently-asked-questions-faqs-about-rems.
  3. Alshammari TM. Drug safety: The concept, inception and its importance in patients’ health. Saudi Pharmaceutical Journal. 2016;24(4):405-412.
  4. A Framework for Benefit-Risk Counseling to Patients About Drugs with a REMS. U.S. Food and Drug Administration https://www.fda.gov/files/about%20fda/published/A-Framework-for-Benefit-Risk-Counseling-to-Patients-About-Drugs-with-a-REMS.pdf.
  5. Science Museum Group. Thalomid (thalidomide) capsules. 2000-590 Science Museum Group Collection Online. Accessed March 13, 2021. https://collection.sciencemuseumgroup.org.uk/objects/co498098/thalomid-thalidomide-capsules-thalidomide.
  6. Science Museum Group. Pair of artificial arms for a child, Roehampton, England, 1964. 1999-579 Science Museum Group Collection Online. Accessed March 13, 2021. https://collection.sciencemuseumgroup.org.uk/objects/co476754/pair-of-artificial-arms-for-a-child-roehampton-england-1964-artificial-arm.
  7. Science Museum Group. Pair of artificial arms for a child, Roehampton, England, 1964. 1999-579 Science Museum Group Collection Online. Accessed March 13, 2021. https://collection.sciencemuseumgroup.org.uk/objects/co476754/pair-of-artificial-arms-for-a-child-roehampton-england-1964-artificial-arm.

Why We Can’t Be Hasty When It Comes to Drug Safety Read More »

Contraceptive Options for Contraindicated Patients

In 2015-2017, it was estimated 64.9% of women in the United States between the ages of 15-49 were using some form of contraception.1 The National Survey of Family Growth (NSFG) reported female sterilization (18.6%), oral contraceptive pills (12.6%), long-acting reversible contraceptives (10.3%) and male condoms (8.7%) were the most popular and common options, however, the degree of usage for each varied largely by age.1 Although some methods of contraception are far more efficacious than others, it is important to also take into consideration other factors such as demographics, side effects, duration, reversibility, and contraindications when offering contraceptive counseling. Likewise, dual protection should always be considered to prevent risks from HIV and STIs since even highly effective methods of contraception such as Intrauterine Device (IUDs) or surgical sterilization do not protect against these infections.2

Contraceptives can be grouped into hormonal and non-hormonal categories. See the interactive diagrams above which compare typical effectiveness per contraceptive method alongside their degree of hormonal properties. Although there are many options to choose from, some patients may find themselves contraindicated for hormonal contraceptives, specifically estrogen. The CDC provides a helpful summary chart (U.S. Medical Eligibility Criteria for Contraceptive Use) which outlines a comprehensive medical eligibility criteria across four categories of severity for several potential conditions and sub conditions.3 For women who find themselves in category 3, it would be wise to consider alternative birth control methods.

Women who find themselves in category 4 are completely contraindicated, typically due to hormonal therapy associated with estrogen releasing products. Patients contraindicated to hormone birth control methods can consider the above options which either circumvent hormones altogether or rely on progestin alone. Note when considering birth control methods, it is important to tailor the best option to the patient. For example, if a patient is looking to space their children out evenly across 3 years, a Nexplanon implant might be a good option. Likewise, a patient who is no longer interested in having children may be better suited for more permanent methods such as sterilization or a long-term IUD.

References

  1. Centers for Disease Control and Prevention. Current Contraceptive Status Among Women Aged 15–49: United States, 2015–2017. Accessed March 1, 2021. https://www.cdc.gov/nchs/products/databriefs/db327.htm.
  2. Centers for Disease Control and Prevention. Contraception. Accessed March 1, 2021. https://www.cdc.gov/reproductivehealth/contraception/index.htm.
  3. Centers for Disease Control and Prevention. US Medical Eligibility Criteria (US MEC) for Contraceptive Use, 2016. Accessed March 1, 2021. https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html.

Contraceptive Options for Contraindicated Patients Read More »

Opioids and Prescribing Patterns in Pain Management

Imagine yourself for a moment walking through your home. You make your way across a table and then suddenly you feel a sharp insurmountable degree of pain in your foot. Is it a staple? Thumbtack? Are you dying? You can be relieved to know my story ends with you simply stepping on a LEGO, although anyone who has done so would tell you it’s no fun (just check out all these memes on the internet).

Pain management is a highly fascinating and challenging area of pharmacy practice. It is typically based on subjective information which can be difficult to quantify, after all one person’s pain tolerance may be vastly different from another. Analgesics like acetaminophen or non-steroidal anti-inflammatory drugs are considered relatively safe options which usually do the trick in helping relieve pain; however, they may not be enough. Many patients with moderate to severe pain will still find themselves needing additional therapy and may therefore end up being prescribed an opioid.

There are two patterns that may arise at this point when we consider opioid management: under prescribing to the point patients might remain in pain or overprescribing to the point patients might misuse. Interestingly, there is evidence variability in opioid prescribing can be traced back to a physician’s specialty and level of training. For example, emergency medicine residents and attending physicians were found to prescribe opioids to a lesser degree as compared to non-emergency medicine providers in an acute care setting.3 Among emergency trained providers, residents were found to prescribe opioids to an even lesser degree than attendings.3

The opioid epidemic is one of the most important health crises we currently have on our hands. Here is an interesting read on how Walmart is currently being sued for supposedly fueling America’s opioid crisis. Furthermore, stigma surrounding substance abuse disorders remains as relevant as ever within our society and is often a cause for patients feeling ostracized or reluctant to seek help should they need it.4

Public health experts have since voiced concerns the current coronavirus pandemic may also further exacerbate the opioid crisis. Vital healthcare services have become interrupted or flipped virtually and this does not even take into account the already extensive degree of isolation patients may feel from their support systems at this time.5 In the figure above you will find ten common non-analgesic effects and properties of opioids, counselling patients on what they can expect from their opioid is understandably vital in making sure these medications are not only used appropriately, but also in mitigating the fear that surrounds opioids as a whole.

References

  1. Portenoy RK, Zankhana M, Ebtesam A. Prevention and management of side effects in patients receiving opioids for chronic pain. UpToDate. UpToDate; 2021. Accessed February 22, 2021.
  2. Rauenzahn S, Del Fabbro E. Opioid management of pain: the impact of the prescription opioid abuse epidemic. Curr Opin Support Palliat Care. 2014;8(3):273-278. doi:10.1097/SPC.0000000000000065.
  3. Leventhal EL, Nathanson LA, Landry AM. Variations in Opioid Prescribing Behavior by Physician Training. West J Emerg Med. 2019;20(3):428-432. doi:10.5811/westjem.2019.3.39311.
  4. National Institute on Drug Abuse. Addressing the Stigma that Surrounds Addiction. Published April 22, 2020. Accessed February 22, 2021. https://www.drugabuse.gov/about-nida/noras-blog/2020/04/addressing-stigma-surrounds-addiction.
  5. Williams B. Expert Perspective: The Opioid Crisis and COVID-19. Published January 26, 2021. Accessed February 22, 2021. https://www.psychiatryadvisor.com/home/topics/addiction/opioid-related-disorder/expert-perspective-the-opioid-crisis-and-covid-19/.

Opioids and Prescribing Patterns in Pain Management Read More »

error: Content is protected !!